Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Michael Stocum to Step Down as Inivata CEO
Search for new CEO is underway
Research Triangle Park, NC and Cambridge, UK, May 8, 2018 -- Inivata, a global clinical cancer genomics company utilizing an industry-leading liquid biopsy platform to transform patient care announces that Michael Stocum has stepped down as CEO to pursue other interests.
Michael Stocum said, "It has been a privilege leading Inivata as we grew from an academic spinout to our current stage of development over the past four years. The company is now entering its next stage of growth with an increasing focus on commercialisation and needs a CEO with a different set of skills."
Jeff Buchalter, Chairman, said, "I would like to thank Mike for his significant contribution to Inivata and wish him well in his future endeavours. Inivata has developed a highly-sensitive liquid biopsy platform that positions it strongly in a fast-growing market. I look forward to the next phase of the Company's development with considerable confidence."
The Company has initiated a search for a new CEO.
About Inivata
Inivata is a global clinical cancer genomics company utilizing a proprietary, industry-leading liquid biopsy platform to transform patient care. Using a simple blood test (liquid biopsy), the analysis of ctDNA is a new lower-cost, less invasive, highly sensitive method for oncologists to diagnose and monitor cancer progression and treatment. The InVision® liquid biopsy platform is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge, combines industry-leading sensitivity with select multi-gene panels to provide clinically actionable information to clinicians. Inivata has established collaborations with world-leading cancer centers and academic institutions, and is partnering with pharmaceutical and biotechnology companies. The Company has a CLIA lab in Research Triangle Park, NC and laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.
Media Contacts:
Consilium Strategic Communications
Chris Gardner/Laura Thornton
[email protected] +44 (0)20 3709 5700
Karen Chandler-Smith
[email protected] +44 (0)7900 430235
